In the phase 3 RASolute 302 trial, daraxonrasib improved overall survival and progression-free survival vs chemotherapy in patients with second-line metastatic pancreatic adenocarcinoma.
May 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
In the phase 3 PEAK trial, bezuclastinib plus sunitinib significantly improved median progression-free survival vs sunitinib alone in patients with advanced gastrointestinal stromal tumors after prior...
The FDA approved Bizengri for adults with advanced, unresectable, or metastatic NRG1 fusion-positive cholangiocarcinoma after prior systemic therapy, providing a new targeted option for an ultra-rare and...
How can primary care clinicians diagnose and manage IBS-C and chronic idiopathic constipation? Joel J. Heidelbaugh, MD, outlines evidence-based treatment options, alarm features, and when to refer to...
A double-blind, placebo-controlled cross-over trial published in BMC Gastroenterology evaluated whether 12 g/day of chicory inulin improves bowel habits, patient-reported outcomes, and gut microbiota...
In a randomized controlled trial of adults with Rome IV irritable bowel syndrome without constipation, investigators found that a Mediterranean-style low-FODMAP diet produced greater symptom improvement,...
A randomized, double-blind trial evaluated whether 4 commonly used nutritional supplements could improve symptoms or microbiota-related outcomes in adults with irritable bowel syndrome.
A post hoc analysis of the ProDeCa randomized trial found that a four-strain psychobiotic regimen added to standard analgesia reduced multidimensional pain scores in postoperative gastrointestinal cancer...
